Ligand Pharmaceuticals (LGND) EBIT Margin Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.55 Bn | 3.77 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,346.00 |
| Dec 31, 2025 | -947.00 |
| Sep 30, 2025 | 3,862.00 |
| Jun 30, 2025 | 59.00 |
| Mar 31, 2025 | -9,131.00 |
| Dec 31, 2024 | 1,519.00 |
| Sep 30, 2024 | 2,686.00 |
| Jun 30, 2024 | -2,946.00 |
| Mar 31, 2024 | -189,115.00 |
| Dec 31, 2023 | -6,758.00 |
| Sep 30, 2023 | -4,180.00 |
| Jun 30, 2023 | -8,546.00 |
| Mar 31, 2023 | -3,366.00 |
| Dec 31, 2022 | -8,747.00 |
| Sep 30, 2022 | -1,528.00 |
| Jun 30, 2022 | 283.00 |
| Mar 31, 2022 | -1,235.00 |
| Dec 31, 2021 | 1,613.00 |
| Sep 30, 2021 | 103.00 |
| Jun 30, 2021 | 3,767.00 |
| Mar 31, 2021 | -4,080.00 |
| Dec 31, 2020 | -1,931.00 |
| Sep 30, 2020 | -3,961.00 |
| Jun 30, 2020 | -656.00 |
| Mar 31, 2020 | -1,151.00 |
| Dec 31, 2019 | -7,960.00 |
| Sep 30, 2019 | -4,438.00 |
| Jun 30, 2019 | -2,933.00 |
| Mar 31, 2019 | 186,884.00 |
| Dec 31, 2018 | 1,203.00 |
| Sep 30, 2018 | 2,756.00 |
| Jun 30, 2018 | 6,213.00 |
| Mar 31, 2018 | 3,221.00 |
| Dec 31, 2017 | 1,624.00 |
| Sep 30, 2017 | 5,847.00 |
| Jun 30, 2017 | 4,606.00 |
| Mar 31, 2017 | 3,308.00 |
| Dec 31, 2016 | 1,464.00 |
| Sep 30, 2016 | 8,188.00 |
| Jun 30, 2016 | 3,119.00 |
| Mar 31, 2016 | 8,898.00 |
| Dec 31, 2015 | 20,330.00 |
| Sep 30, 2015 | 24,948.00 |